March 14, 2023 10:57 AM EDT
R&D

Servi­er says its next IDH in­hibitor has passed PhI­II, but no reg­u­la­to­ry time­line yet

Lei Lei Wu

News Reporter

Servi­er’s IDH in­hibitor vo­rasi­denib has passed its Phase III tri­al in low-grade glioma, the com­pa­ny an­nounced Tues­day morn­ing. How­ev­er, it left …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times